Q3 2024 Torrent Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Sustained performance in the branded segment, accounting for 72% of the quarter's revenue.
- Steady increase in revenues in Germany due to incremental tender wins.
- Stable US-based business with new launches expected to enhance performance starting from Q1 of the next fiscal year.
- Operating EBITDA margins improved to 31.8%, indicating enhanced cost efficiencies.
- India revenue grew by 12%, driven by new launches, top brands, and focused therapies.
- Forex translation losses of INR35 crores, though expected to reverse in coming quarters.
- US revenues down by 7% YoY, despite sequential growth.
- Gross margin dipped slightly due to the mix of increased US sales.
- Pending regulatory inspection for the Indrad facility.
- Challenges in expanding the Curatio business beyond its stronghold regions.
Ladies and gentlemen, good day and welcome to the Q3 FY24 Earnings Conference Call of Torrent Pharma. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Sudhir Menon, Chief Financial Officer and Executive Director, Finance. Thank you and over to you, sir.
Thank you. Good afternoon and thank you for joining us for the Third Quarter Earnings Call for FY24. This quarter highlights a sustained performance in the branded segment, which accounted for 72% this quarter; steady increase in revenues quarter-on-quarter in Germany on the back of incremental tender wins we've had, some of them starting in the next fiscal as well; and a stable US-based business. We should see new launches in the US starting from quarter one of the next fiscal, which will further help in enhancing the overall company performance from next year.
Our efforts to enhance cost efficiencies are playing out well in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
